Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452

The Statistical Analysis of Failure Time Data.

Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875

Validation of a combined comorbidity index

Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587

International scoring system for evaluating prognosis in myelodysplastic syndromes

Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427

Regression modelling strategies for improved prognostic prediction

Harrell, F. E., Lee, K. L., Califf, R. M., Pryor, D. B., & Rosati, R. A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030207 · Cited by 1,804

Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives

Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717

The pre-therapeutic classification of co-morbidity in chronic disease

Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544

Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia

Storb, R. F., Deeg, H. J., Whitehead, J., Appelbaum, F. R., Beatty, P. G., Bensinger, W., Buckner, C. D., Clift, R. A., Doney, K., Farewell, V. T., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

McSweeney, P. A., Niederwieser, D. W., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,386

Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation

Nawas, M. T., Andreadis, C. B., Martin, T. G., Wolf, J. L., Ai, W. Z., Kaplan, L. D., Mannis, G. N., Logan, A. C., Damon, L. E., Huang, C., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.01.028 · Cited by 42

A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation

Bejanyan, N., Pidala, J. A., Wang, X., Thapa, R., Nishihori, T., Elmariah, H., Lazaryan, A., Khimani, F., Davila, M. L., Mishra, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003779 · Cited by 44

Early Lymphocyte Recovery and Outcomes after Umbilical Cord Blood Transplantation (UCBT) for Hematologic Malignancies

Burke, M. J., Vogel, R. I., Janardan, S. K., Brunstein, C. G., Smith, A. R., Miller, J. S., Weisdorf, D. J., Wagner, J. E., & Verneris, M. R. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.08.022 · Cited by 44

Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome

Porta, M. G. D., & Malcovati, L. (2009) · Haematologica · doi:10.3324/haematol.2009.005702 · Cited by 44

Salvage chemotherapy followed by granulocyte colony‐stimulating factor‐primed donor leukocyte infusion with graft‐vs.‐host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes

Mo, X., Zhang, X., Xu, L., Wang, Y., Yan, C., Chen, H., Chen, Y., Han, W., Wang, F., Wang, J., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12591 · Cited by 43

Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation

Bokhari, S. W. I., Watson, L., Nagra, S., Cook, M. A., Byrne, J., Craddock, C., & Russell, N. H. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.138 · Cited by 43

Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease

Devillier, R., Fürst, S., Cheikh, J. E., Castagna, L., Harbi, S., Granata, A., Crocchiolo, R., Oudin, C., Mohty, B., Bouabdallah, R., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.11.030 · Cited by 43

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society

Baron, F., Zachée, P., Maertens, J. A., Kerre, T. C. C., Ory, A., Seidel, L., Graux, C., Lewalle, P., van Gelder, M., Theunissen, K., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0098-9 · Cited by 43

RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT

Baron, F., Ruggeri, A., Beohou, E., Labopin, M., Sanz, G. F., Milpied, N. J., Michallet, M., Bacigalupo, A. P., Blaise, D., Sierra, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9599 · Cited by 43

T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia

How, J., Slade, M., Vu, K., DiPersio, J. F., Westervelt, P., Uy, G. L., Abboud, C. N., Vij, R., Schroeder, M. A., Fehniger, T. A., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.01.068 · Cited by 43

IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation

Betts, B. C., Pidala, J., Kim, J., Mishra, A., Nishihori, T., Perez, L. E., Ochoa-Bayona, J. L., Khimani, F., Walton, K., Bookout, R., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.153072 · Cited by 43

Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation

Mo, X., Zhang, X., Xu, L., Wang, Y., Yan, C., Chen, H., Chen, Y., Han, W., Wang, F., Wang, J., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2960-7 · Cited by 43

Current Graft-versus-Host Disease–Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant

Solomon, S. R., Sizemore, C. A., Zhang, X., Ridgeway, M., Solh, M., Morris, L. E., Holland, H. K., & Bashey, A. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.02.022 · Cited by 43

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

Chhabra, S., Ahn, K. W., Hu, Z., Jain, S., Assal, A., Černý, J., Copelan, E. A., Daly, A. S., DeFilipp, Z. M., Gadalla, S. M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024844 · Cited by 43

Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission

Konuma, T., Kanda, J., Yamasaki, S., Harada, K., Shimomura, Y., Terakura, S., Mizuno, S., Uchida, N., Tanaka, M., Doki, N., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.023 · Cited by 43

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients

Ljungman, P. T., Bermúdez, A., Logan, A. C., Kharfan‐Dabaja, M. A., Chevallier, P., Martino, R., Wulf, G. G., Selleslag, D., Kakihana, K., Langston, A. A., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100787 · Cited by 42

PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation

Desai, N., Altareb, M., Remberger, M., Chen, C. C. L., Moya, T. A., Al‐Shaibani, E., Novitzky‐Basso, I., Pašić, I., Lam, W., Michelis, F. V., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014781 · Cited by 42

Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia‐negative acute lymphoblastic leukemia: No difference in the high‐ and low‐risk groups

Mo, X., Xu, L., Zhang, X., Liu, D., Wang, Y., Chen, H., Yan, C., Chen, Y., Han, W., Wang, F., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29146 · Cited by 42

A Two-Step Approach to Myeloablative Haploidentical Transplantation: Low Nonrelapse Mortality and High Survival Confirmed in Patients with Earlier Stage Disease

Grosso, D. A., Gaballa, S. R., Alpdoğan, Ö., Carabasi, M. H., Filicko-O'Hara, J. E., Kasner, M. T., Martinez‐Outschoorn, U., Wagner, J. L., O’Hara, W., Rudolph, S., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.019 · Cited by 42

Results of a prospective multicentre myeloablative double‐unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia

Barker, J. N., Fei, M., Karanes, C., Horwitz, M. E., Devine, S. M., Kindwall‐Keller, T. L., Chakrabarty, J. H., Adams, A. J., Logan, B. R., Navarro, W. H., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13136 · Cited by 42

Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity

Elstrom, R., Martin, P., Rúa, S. M. H., Shore, T. B., Furman, R. R., Ruan, J., Pearse, R. N., Coleman, M., Mark, T. M., Leonard, J. P., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.23108 · Cited by 42

Reduced-intensity conditioned allogeneic SCT in adults with AML

Reshef, R., & Porter, D. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.7 · Cited by 42

Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

Wetzler, M., Mrózek, K., Kohlschmidt, J., Dombret, H., Döhner, H., Pilorge, S., Krug, U. O., Carroll, A. J., Larson, R. A., Marcucci, G., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.092072 · Cited by 42

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission

Walter, R. B., Sandmaier, B. M., Storer, B. E., Godwin, C. D., Buckley, S. A., Pagel, J. M., Sorror, M. L., Deeg, H. J., Storb, R. F., & Appelbaum, F. R. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.09.022 · Cited by 42

Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia

Klepin, H. D. (2014) · Hematology · doi:10.1182/asheducation-2014.1.8 · Cited by 42

Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years)

Pohlen, M., Groth, C., Sauer, T., Görlich, D., Mesters, R. M., Schliemann, C., Lenz, G., Müller‐Tidow, C., Büchner, T., Berdel, W. E., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.156 · Cited by 42

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices

Ma, E., Bonthapally, V., Chawla, A., Lefèbvre, P., Swords, R. T., Lafeuille, M.-H., Fortier, J., Émond, B., Duh, M. S., & Dezube, B. J. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.006 · Cited by 42

Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation

Shah, M. V., Saliba, R. M., Rondón, G., Chen, J. J., Soebbing, D., Rus, I., Alousi, A. M., Oran, B., Kebriaei, P., Qazilbash, M. H., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0367-2 · Cited by 42

Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation

Yokoyama, H., Morishima, Y., Fuji, S., Uchida, N., Takahashi, S., Onizuka, M., Tanaka, M., Ohno, Y., Eto, T., Ozawa, Y., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.001 · Cited by 42

Use of geriatric assessment in hematopoietic cell transplant

Jayani, R., Rosko, A. E., Olin, R. L., & Artz, A. S. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.09.012 · Cited by 41

Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years

Belotti, A., Ribolla, R., Cancelli, V., Crippa, C., Bianchetti, N., Ferrari, S., Bottelli, C., Cattaneo, C. M., Tucci, A., Barrigon, C. D. L. F., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25797 · Cited by 39

Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation

Salas, M. Q., Atenafu, E. G., Bascom, O., Wilson, L., Lam, W., Law, A., Pašić, I., Kim, D. D. H., Michelis, F. V., Al‐Shaibani, Z., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0979-1 · Cited by 42

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Morsink, L. M., Sandmaier, B. M., Othus, M. K. D., Palmieri, R., Granot, N., Bezerra, E. D., Wood, B. L., Mielcarek, M. B., Schoch, G. H., Davis, C., et al. (2020) · Cancers · doi:10.3390/cancers12092339 · Cited by 42

The hematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) is an outcome predictor for partially matched related donor transplantation

Mo, X., Xu, L., Liu, D., Zhang, X., Chen, H., Chen, Y., Han, W., Wang, Y., Wang, F., Wang, J., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23443 · Cited by 42

Chronic lymphocytic leukemia: planning for an aging population

Gribben, J. G. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.127 · Cited by 42

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Malki, M. M. A., Bo‐Subait, S., Logan, B. R., Olson, J. A., Kou, J., Smith, S. C., Leckrone, E., Wu, J., Stefanski, H. E., Auletta, J. J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00856 · Cited by 47

A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs

Mato, A. R., & Porter, D. L. (2015) · Blood · doi:10.1182/blood-2015-03-585091 · Cited by 41

Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis

Leković, D., Gotić, M., Peruničić-Jovanović, M., Vidović, A., Bogdanovic, A. D., Janković, G., Čokić, V. P., & Milic, N. M. (2014) · Medical Oncology · doi:10.1007/s12032-014-0869-8 · Cited by 41

Comorbidities and FLT3‐ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients

Breccia, M., Frustaci, A. M., Cannella, L., Stefanizzi, C., Latagliata, R., Cartoni, C., Diverio, D., Guarini, A. R., Nanni, M., Rago, A., et al. (2009) · Hematological Oncology · doi:10.1002/hon.889 · Cited by 41

Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency

Rizzi, M., Neumann, C., Fielding, A. K., Marks, R., Goldacker, S., Thaventhiran, J. E. D., Tarzi, M. D., Schlesier, M., Salzer, U., Eibel, H., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.055 · Cited by 41

Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation

Mayo, S. J., Messner, H. A., Rourke, S. B., Howell, D., Victor, J. C., Kuruvilla, J. G., Lipton, J. H., Gupta, V. K., Kim, D. D., Piescic, C., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.2 · Cited by 41

Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?

Potdar, R. R., Varadi, G., Fein, J. A., Labopin, M., Nagler, A., & Shouval, R. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.07.028 · Cited by 41

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades

Cooper, J. P., Storer, B. E., Granot, N., Gyurkocza, B., Sorror, M. L., Chauncey, T. R., Shizuru, J. A., Franke, G., Maris, M. B., Boyer, M. J., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.248187 · Cited by 41

Feasibility and safety of exercise training and nutritional support prior to haematopoietic stem cell transplantation in patients with haematologic malignancies

Rupnik, E., Škerget, M., Sever, M., Zupan, I. P., Ogrinec, M., Ursic, B., Kos, N., Černelč, P., & Zver, S. (2020) · BMC Cancer · doi:10.1186/s12885-020-07637-z · Cited by 41

Incidence and Risk Factors of Early Bacterial Infections after Unrelated Cord Blood Transplantation

Yazaki, M., Atsuta, Y., Kato, K., Kato, S., Taniguchi, S., Takahashi, S., Ogawa, H., Kouzai, Y., Kobayashi, T., Inoue, M., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.12.508 · Cited by 41

Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia

Shimomura, Y., Sobue, T., Hirabayashi, S., Kondo, T., Mizuno, S., Kanda, J., Fujino, T., Kataoka, K., Uchida, N., Eto, T., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01474-0 · Cited by 40

Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation

Bruno, A., Gurnari, C., Alexander, T., Snowden, J. A., & Greco, R. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.02.017 · Cited by 40

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation

Al‐Homsi, A. S., Cirrone, F., Wo, S., Cole, K., Suarez‐Londono, J. A., Gardner, S. L., Hsu, J., Stocker, K., Bruno, B., Goldberg, J. D., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010545 · Cited by 40

Evaluation of the Feasibility and Efficacy of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma

Muta, T., Miyamoto, T., Fujisaki, T., Ohno, Y., Kamimura, T., Kato, K., Takenaka, K., Iwasaki, H., Eto, T., Takamatsu, Y., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8390 · Cited by 40

Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT

Castagna, L., Fürst, S., Marchetti, N., Cheikh, J. E., Faucher, C., Mohty, M., Bouabdallah, R., Vey, N., Stoppa, A., Esterni, B., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.227 · Cited by 40

Allotransplantation for chronic lymphocytic leukemia

Dreger, P. (2009) · Hematology · doi:10.1182/asheducation-2009.1.602 · Cited by 40

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial

Nakamae, H., Storer, B. E., Storb, R. F., Storek, J., Chauncey, T. R., Pulsipher, M. A., Petersen, F. B., Wade, J. C., Maris, M. B., Bruno, B., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.11.004 · Cited by 40

Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation

Bejanyan, N., Rogosheske, J., DeFor, T. E., Lazaryan, A., Esbaum, K., Holtan, S. G., Arora, M., MacMillan, M. L., Weisdorf, D. J., Jacobson, P. A., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.01.023 · Cited by 40

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non-Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation

Pollack, S. M., Steinberg, S. M., Odom, J., Dean, R. M., Fowler, D. H., & Bishop, M. R. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.023 · Cited by 40

Status of Natural Killer Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome

Hattori, N., Saito, B., Sasaki, Y., Shimada, S., Murai, S., Abe, M., Baba, Y., Watanuki, M., Fujiwara, S., Kawaguchi, Y., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.05.007 · Cited by 40

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial

Pigneux, A., Béné, M. C., Salmi, L., Dumas, P., Delaunay, J., Bonmati, C., Guièze, R., Luquet, I., Cornillet‐Lefèbvre, P., Delabesse, É., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.7366 · Cited by 40

Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Hattori, N., Kawaguchi, Y., Sasaki, Y., Shimada, S., Murai, S., Abe, M., Baba, Y., Watanuki, M., Fujiwara, S., Arai, N., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.01.013 · Cited by 41

We do still transplant CML, don’t we?

Craddock, C. (2018) · Hematology · doi:10.1182/asheducation-2018.1.177 · Cited by 40

A prospective observational study of immune reconstitution following transplantation with post‐transplant reduced‐dose cyclophosphamide from HLA ‐haploidentical donors

Nakamae, H., Fujii, K., Nanno, S., Okamura, H., Nakane, T., Koh, H., Nakashima, Y., Nakamae, M., Hirose, A., Teshima, T., et al. (2019) · Transplant International · doi:10.1111/tri.13494 · Cited by 40

Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma

Utsunomiya, A. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02235 · Cited by 41

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

Oran, B., Garcia‐Manero, G., Saliba, R. M., Alfayez, M., Alatrash, G., Ciurea, S. O., Jabbour, E. J., Mehta, R. S., Popat, U., Ravandi, F., et al. (2020) · Cancer · doi:10.1002/cncr.32796 · Cited by 40

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia

Kim, H. T., Shaughnessy, C. J., Rai, S. C., Reynolds, C. G., Ho, V. T., Cutler, C. S., Koreth, J., Gooptu, M., Romee, R., Nikiforow, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002184 · Cited by 40

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation

Gagelmann, N., Badbaran, A., Beelen, D. W., Salit, R. B., Stölzel, F., Rautenberg, C., Becker, H., Radujkovic, A., Panagiota, V., Bogdanov, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003600 · Cited by 40

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Dahi, P. B., Lee, J., Devlin, S. M., Ruiz, J. D., Maloy, M., Rondon-Clavo, C., Petrlik, E., Tamari, R., Shah, G. L., Scordo, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004167 · Cited by 40

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Bastos‐Oreiro, M., Gutierrez, A. M., Reguera, J. L., Iacoboni, G., López‐Corral, L., Terol, M. J., Ortiz‐Maldonado, V., Sanz, J., Guerra, L. M., Bailén, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.855730 · Cited by 40

Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation

Brunstein, C. G., Cantero, S., Cao, Q., Majhail, N. S., McClune, B. L., Burns, L. J., Tomblyn, M. R., Miller, J. S., Blazar, B. R., McGlave, P. B., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.013 · Cited by 40

The Hematopoietic Cell Transplantation-Specific Comorbidity Index Fails to Predict Outcomes in High-Risk AML Patients Undergoing Allogeneic Transplantation—Investigation of Potential Limitations of the Index

Birninger, N., Bornhäuser, M., Schaich, M. A., Ehninger, G., & Schetelig, J. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.06.009 · Cited by 40

Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101

Ritchie, E. K., Klepin, H. D., Storrick, E. M., Major, B. T., Le‐Rademacher, J. G., Wadleigh, M., Walker, A., Larson, R. A., & Roboz, G. J. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006872 · Cited by 39

Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT

Kharfan‐Dabaja, M. A., Labopin, M., Bazarbachi, A. A., Hamladji, R. M., Blaise, D., Socié, G., Lioure, B., Bermúdez, A., López‐Corral, L., Or, R., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.133 · Cited by 39

High-Dose Total Body Irradiation and Myeloablative Conditioning before Allogeneic Hematopoietic Cell Transplantation: Time to Rethink?

Mohty, M., Malard, F., & Savani, B. N. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.09.010 · Cited by 42

Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients

Breccia, M., Federico, V., Latagliata, R., Mercanti, C., D’Elia, G. M., Cannella, L., Loglisci, G., Salaroli, A., Santopietro, M., & Alimena, G. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.06.005 · Cited by 39

Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation

Modi, D., Jang, H., Kim, S., Deol, A., Ayash, L. J., Bhutani, D., Lum, L. G., Ratanatharathorn, V., Manasa, R., Mellert, K., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24435 · Cited by 39

How and when to decide between epigenetic therapy and chemotherapy in patients with AML

Dombret, H., & Itzykson, R. (2017) · Hematology · doi:10.1182/asheducation-2017.1.45 · Cited by 43

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis

Gooptu, M., Kim, H. T., Ho, V. T., Alyea, E. P., Koreth, J., Armand, P. A., Ritz, J., Nikiforow, S., Glotzbecker, B. E., Nageshwar, P. K., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.03.011 · Cited by 40

Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting

Nilsson, C. C., Hulegårdh, E., Garelius, H. G., Möllgård, L., Brune, M. L., Wåhlin, A., Lenhoff, S., Frödin, U., Remberger, M., Höglund, M., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.05.038 · Cited by 38

Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

Carré, M., Porcher, R., Finke, J., Ehninger, G., Köster, L., Beelen, D. W., Ganser, A., Volin, L., Lozano, S., Friis, L. S., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.10.015 · Cited by 39

Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia in First or Subsequent Remission: Weighing Prognostic Markers Predicting Relapse and Risk Factors for Non-relapse Mortality

Meijer, E., & Cornelissen, J. J. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.015 · Cited by 39

Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia

Hamadani, M., Awan, F. T., & Copelan, E. A. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.02.019 · Cited by 38

Comparable Outcomes after Nonmyeloablative Hematopoietic Cell Transplantation with Unrelated and Related Donors

Mielcarek, M. B., Storer, B. E., Sandmaier, B. M., Sorror, M. L., Maloney, D. G., Petersdorf, E. W., Martin, P. J., & Storb, R. F. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.09.004 · Cited by 39

Allogeneic Transplantation for the Elderly Patient With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Lima, M. J. G. D., & Giralt, S. A. (2006) · Seminars in Hematology · doi:10.1053/j.seminhematol.2006.01.004 · Cited by 39

Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts

Yahng, S., Kim, M., Kim, T., Jeon, Y., Yoon, J., Shin, S., Lee, S., Eom, K., Lee, S., Min, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12511 · Cited by 39

Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia

Matthews, A. H., Perl, A. E., Luger, S. M., Gill, S. I., Lai, C., Porter, D. L., Skuli, S. J., Bruno, X. J., Carroll, M. P., Freyer, C. W., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26991 · Cited by 39

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

Hyder, M. A., Dimitrova, D., Sabina, R., DeVries, A., McCune, J. S., McAdams, M. J., Flomerfelt, F. A., McKeown, C., Sadler, J. L., Chai, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014879 · Cited by 38

Pushing the envelope—nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation

Pingali, S. R., & Champlin, R. E. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.61 · Cited by 38

High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: A Single Institution Experience at All India Institute of Medical Sciences, New Delhi, Using Non-Cryopreserved Peripheral Blood Stem Cells

Kayal, S., Sharma, A., Iqbal, S., Tilak, T., Cyriac, S. L., & Raina, V. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.09.001 · Cited by 38

High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission

Candoni, A., Marchi, F. D., Zannier, M. E., Lazzarotto, D., Fili, C. C., Dubbini, M. V., Rabassi, N., Toffoletti, E., Lau, B. W., & Fanin, R. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.10.010 · Cited by 38

Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

Baron, F., Labopin, M., Ruggeri, A., Cornelissen, J. J., Meijer, E., Sengeloev, H., Niederwieser, D. W., de Groot, M. R., Schouten, H. C., Milpied, N. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3622 · Cited by 38

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT

on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), Piemontese, S., Boumendil, A., Labopin, M., Schmid, C., Ciceri, F., Arcese, W., Koç, Y., Gulbas, Z., Tischer, J., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0751-4 · Cited by 38

CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Dreger, P., Dietrich, S., Schubert, M., Selberg, L., Bondong, A., Wegner, M., Stadtherr, P., Kimmich, C. R., Kosely, F., Schmitt, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003036 · Cited by 38

Pretransplant Predictors and Posttransplant Sequels of Acute Kidney Injury after Allogeneic Stem Cell Transplantation

Kagoya, Y., Kataoka, K., Nannya, Y., & Kurokawa, M. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.07.010 · Cited by 38

Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial

Blaise, D., Devillier, R., Corroller, A. L., Boher, J., Boyer-Chammard, A., Tabrizi, R., Chevallier, P., Fegueux, N., Sîrvent, A., Michallet, M., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.113571 · Cited by 38

Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies

Blaise, D., Farnault, L., Faucher, C., Marchetti, N., Fürst, S., Cheikh, J. E., Ladaique, P., Vey, N., Bouabdallah, R., & Stoppa, A. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.08.012 · Cited by 37

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant

Rhee, J., Pillai, R. K., He, T., Bosworth, A., Chen, S., Atencio, L., Oganesyan, A., Peng, K., Guzman, T., Lukas, K., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.4105 · Cited by 35

Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Johnston, C., Harrington, R. D., Jain, R., Schiffer, J. T., Kiem, H., & Woolfrey, A. E. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.08.006 · Cited by 37

Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Myeloid Leukemia

Hamadani, M., Mohty, M., & Kharfan‐Dabaja, M. A. (2011) · Cancer Control · doi:10.1177/107327481101800404 · Cited by 37

Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation

Nakasone, H., Kurosawa, S., Yakushijin, K., Taniguchi, S., Murata, M., Ikegame, K., Kobayashi, T., Eto, T., Miyamura, K., Sakamaki, H., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23436 · Cited by 37

Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study

Schmid, C., Schleuning, M., Tischer, J., Holler, E., Haude, K.-H., Braess, J., Haferlach, C., Baurmann, H., Oruzio, D. V., Hahn, J. R., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.15 · Cited by 37

Validation of the acute leukemia‐EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi‐center GITMO cohort

Shouval, R., Bonifazi, F., Fein, J. A., Boschini, C., Oldani, E., Labopin, M., Raimondi, R., Sacchi, N., Dabash, O., Unger, R., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24677 · Cited by 37

Oral health of adult patients undergoing hematopoietic cell transplantation. Pre-transplant assessment and care

Bogusławska-Kapała, A., Hałaburda, K., Rusyan, E., Gołąbek, H., & Strużycka, I. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2932-y · Cited by 36

Allogeneic Stem Cell Transplantation in Myelofibrosis

Jain, T., Mesa, R. A., & Palmer, J. M. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.05.007 · Cited by 38

TRANSPLANTATION Hematopoietic cell transplantation (HCT)–specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Sorror, M. L., Maris, M. B., Storb, R. F., Baron, F., S, B. M., Maloney, D. G., & Storer, B. E. (2016)

Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weights

Sorror, M. L., Storer, B. E., & Storb, R. F. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.131 · Cited by 9

54: Hematopoietic cell transplantation-comorbidity index (HCT-CI)

Kassar, M., Shell, K., Gregory, S. A., Venugopal, P., Shammo, J. M., & Fung, H. C. H. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.12.057

Hematopoietic Cell Transplantation-Specific Comorbidity Index To Predict Non-Relapse Mortality and Survival after Allografting.

Kato, R., Fukuda, T., Usui, E., Yamasaki, S., Maruyama, D., Morita, Y., Kim, S., Mori, S., Tanosaki, R., Tajima, K., et al. (2005) · Blood · doi:10.1182/blood.v106.11.2731.2731 · Cited by 1

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study

Sorror, M. L., Logan, B. R., Zhu, X., Rizzo, J. D., Cooke, K. R., McCarthy, P. L., Ho, V. T., Horowitz, M. M., & Pasquini, M. C. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.004 · Cited by 222